News for Jasper Therapeutics Stock (JSPR)

Jasper Therapeutics Announces Development Prioritization of Briquilimab in Chronic Diseases, Including Urticaria and Lower-Risk MDS, and Stem Cell Transplant for Sickle Cell Disease and Other Rare Diseases

GlobeNewsWire • 01/10/23

Jasper Therapeutics Announces European Union Orphan Drug Designation for Briquilimab as a Conditioning Treatment for Patients Prior to Receiving a Stem Cell Transplant

GlobeNewsWire • 01/04/23

Jasper Therapeutics shares jump after announcing new clinical data

Market Watch • 01/03/23

Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia

GlobeNewsWire • 01/03/23

Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewsWire • 11/10/22

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

GlobeNewsWire • 09/26/22

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant

GlobeNewsWire • 09/15/22

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewsWire • 08/12/22

All You Need to Know About Jasper Therapeutics, Inc. (JSPR) Rating Upgrade to Buy

Zacks Investment Research • 07/15/22

Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

GlobeNewsWire • 06/23/22

Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference

GlobeNewsWire • 06/07/22

Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022

GlobeNewsWire • 06/06/22

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

GlobeNewsWire • 05/17/22

Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

GlobeNewsWire • 05/12/22

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

GlobeNewsWire • 04/28/22

Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

GlobeNewsWire • 04/26/22

Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting

GlobeNewsWire • 03/31/22

Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team

GlobeNewsWire • 03/21/22

Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

GlobeNewsWire • 03/18/22

Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

GlobeNewsWire • 03/10/22

Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer

GlobeNewsWire • 02/28/22

Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

GlobeNewsWire • 02/24/22

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Market Watch • 02/06/22

Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting

GlobeNewsWire • 12/08/21

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Seeking Alpha • 11/28/21